| Home | Generics | Biosimilars | Docs & Positions | Facts & Figures | Press Room | Conferences | Links |
![]() Driving innovation through competition.About GenericsOverviewThe Science of Generic MedicinesOverviewAffordability & Sustainable HealthOverviewIntellectual PropertyOverview IP Rights Pharma Patents Data Exclusivity “Evergreening”Further ResourcesBibliography |
Intellectual PropertyArticles in this Section:Types of Intellectual Property RightsThere are four main types of intellectual property rights: trade marks, design registration, copyright and patents ... Pharmaceutical PatentsOriginator pharmaceutical companies practise what are euphemistically known as “total product strategies” or “lifecycle maximisation” by seeking to obtain as many patents as possible ... Data ExclusivityData Exclusivity guarantees additional market protection for originator pharmaceuticals by preventing health authorities from accepting applications for generic medicines during the period of exclusivity ... EvergreeningOne form of evergreening occurs when the originator manufacturer “stockpiles” patent protection by obtaining separate 20-year patents on multiple attributes of a single product. But many other evergreening strategies exist ... |
| Copyright © 2004 EGA - European Generic medicines Association • • Cascading Pop-up Menus ©Angus Turnbull |
